Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Annaly Capital Management, Inc. (NLY) vs 10X Genomics Inc (TXG) Price & Performance

Annaly Capital Management, Inc.Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Annaly Capital Management, Inc. vs 10X Genomics Inc — how do they compare? Annaly Capital Management, Inc. trades at $23.25 (market cap $17.44B), while 10X Genomics Inc trades at $59.15 (market cap $7.61B). The key difference: Annaly Capital Management, Inc. is far larger — about 2.3× 10X Genomics Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

NLYTXG
Market Cap
$17.44B$7.61B
Sector
FinancialsHealth
52-Week High
$24.40$58.57
52-Week Low
$20.21$11.34
Dividend Yield
12.96%
Enterprise Value
$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Annaly Capital Management, Inc.

NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.

Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About Annaly Capital Management, Inc.

Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.

Read more on NLY

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG